Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
26 mars 2015 09h00 HE
|
Zogenix
SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results
10 mars 2015 16h05 HE
|
Zogenix
Clinical and Regulatory Update
Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™
On track to begin...
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million
10 mars 2015 16h05 HE
|
Zogenix
Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline
Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET
Agreement...
Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results
02 mars 2015 16h05 HE
|
Zogenix
SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
10 févr. 2015 16h01 HE
|
Zogenix
SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix to Participate in Leerink Global Healthcare Conference
05 févr. 2015 09h00 HE
|
Zogenix
SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
30 janv. 2015 19h05 HE
|
Zogenix
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
Zogenix Provides Business Update
12 janv. 2015 07h30 HE
|
Zogenix
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
03 déc. 2014 16h30 HE
|
Zogenix
SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
01 déc. 2014 08h30 HE
|
Zogenix
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...